Biotechnology - Genomic and Proteomics/Open Business models in BGP

Report April 2009

Answer

• TDI “A kernel for the Tropical Disease Initiative”, Leticia Ort’ et. al., Nature Publishing Group,
  • Problem it aims to address: open source drug development has not been successful because there lacks a critical mass of publicly available data. Focus on tropical diseases
  • Methodology: develop computational pipeline (e.g. open source data sets) for developing the following: structure modeling of target proteins
  • predictions of ligant bonding locations: (e.g., http://www.thesynapticleap.org/), public-private partnerships (e.g., http://www.mmv.org/) and private foundations (e.g., http://www.gatesfoundation.org/);
  • predict structures of protein sequences
  • products created from using the software do not seem to be required to be put in the public domain
  • Uses Science Commons protocol for implementing Open Access Data ((http://sciencecommons.org/projects/publishing/open-access-dataprotocol/)
  • Open Source Biotechnology Project, Open source biotechnology?, http://rsss.anu.edu.au/~janeth/OSBiotech.html

Navigation

Bibliography for Item 12 in BGP
Biotechnology_-_Genomic_and_Proteomics